These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 32513796)
41. In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Waites KB; Crabb DM; Liu Y; Duffy LB Antimicrob Agents Chemother; 2016 Dec; 60(12):7502-7504. PubMed ID: 27671057 [TBL] [Abstract][Full Text] [Related]
42. Discovery of a Potent Picolinamide Antibacterial Active against Speri E; Janardhanan J; Masitas C; Schroeder VA; Lastochkin E; Wolter WR; Fisher JF; Mobashery S; Chang M ACS Infect Dis; 2020 Sep; 6(9):2362-2368. PubMed ID: 32786277 [TBL] [Abstract][Full Text] [Related]
43. The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile. Wultańska D; Piotrowski M; Pituch H Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1391-1399. PubMed ID: 32140903 [TBL] [Abstract][Full Text] [Related]
44. Omadacycline is active Heine HS; Drusano G; Purcell BK; Anastasiou D; Tanaka SK; Serio AW Antimicrob Agents Chemother; 2024 Sep; 68(9):e0059524. PubMed ID: 39133023 [No Abstract] [Full Text] [Related]
45. Inhibitory effect of Brazilian red propolis on planktonic and biofilm forms of Clostridioides difficile. Costa CL; Azevedo CP; Quesada-Gómez C; Brito GAC; Regueira-Neto MDS; Guedes GMM; Rocha MFG; Sidrim JJC; Cordeiro RA; Carvalho CBM; Castelo-Branco DSCM Anaerobe; 2021 Jun; 69():102322. PubMed ID: 33515722 [TBL] [Abstract][Full Text] [Related]
46. In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria. Tyrrell KL; Citron DM; Merriam CV; Leoncio E; Goldstein EJC Anaerobe; 2018 Dec; 54():39-41. PubMed ID: 30096588 [TBL] [Abstract][Full Text] [Related]
47. Antibacterial activity and mechanism of action of chitosan nanofibers against toxigenic Clostridioides (Clostridium) difficile Isolates. Shahini Shams Abadi M; Mirzaei E; Bazargani A; Gholipour A; Heidari H; Hadi N Ann Ig; 2020; 32(1):72-80. PubMed ID: 31713579 [TBL] [Abstract][Full Text] [Related]
48. Micrococcin P2 Targets Son YJ; Kim YR; Oh SH; Jung S; Ciufolini MA; Hwang HJ; Kwak JH; Pai H J Nat Prod; 2022 Aug; 85(8):1928-1935. PubMed ID: 35816693 [No Abstract] [Full Text] [Related]
49. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran. Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133 [TBL] [Abstract][Full Text] [Related]
50. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile. Skinner K; Birchall S; Corbett D; Thommes P; Locher HH J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178 [TBL] [Abstract][Full Text] [Related]
51. Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile. Pu M; Cho JM; Cunningham SA; Behera GK; Becker S; Amjad T; Greenwood-Quaintance KE; Mendes-Soares H; Jones-Hall Y; Jeraldo PR; Chen J; Dunny G; Patel R; Kashyap PC Gastroenterology; 2021 Feb; 160(3):941-945.e8. PubMed ID: 33197449 [TBL] [Abstract][Full Text] [Related]
52. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile. Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190 [TBL] [Abstract][Full Text] [Related]
53. Comparison of antibacterial activities and resistance mechanisms of omadacycline and tigecycline against Enterococcus faecium. Liu X; Zhang C; Zhao Y; Cheng H; Wang Y; Wang Z; Shang Y; Zheng J; Yu Z; Shi Y J Antibiot (Tokyo); 2022 Aug; 75(8):463-471. PubMed ID: 35760902 [TBL] [Abstract][Full Text] [Related]
54. Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections. Abutaleb NS; Seleem MN Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253206 [No Abstract] [Full Text] [Related]
56. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Tanaka SK; Steenbergen J; Villano S Bioorg Med Chem; 2016 Dec; 24(24):6409-6419. PubMed ID: 27469981 [TBL] [Abstract][Full Text] [Related]
57. Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. Mendes RE; Huband MD; Streit JM; Castanheira M; Flamm RK Diagn Microbiol Infect Dis; 2020 Jul; 97(3):115054. PubMed ID: 32376058 [TBL] [Abstract][Full Text] [Related]
58. Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Budi N; Godfrey JJ; Safdar N; Shukla SK; Rose WE Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33649111 [No Abstract] [Full Text] [Related]
59. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Phanchana M; Phetruen T; Harnvoravongchai P; Raksat P; Ounjai P; Chankhamhaengdecha S; Janvilisri T Sci Rep; 2020 Apr; 10(1):6497. PubMed ID: 32300130 [TBL] [Abstract][Full Text] [Related]
60. Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico. Martínez-Meléndez A; Tijerina-Rodríguez L; Morfin-Otero R; Camacho-Ortíz A; Villarreal-Treviño L; Sánchez-Alanís H; Rodríguez-Noriega E; Baines SD; Flores-Treviño S; Maldonado-Garza HJ; Garza-González E Microb Drug Resist; 2018 May; 24(4):386-392. PubMed ID: 29485939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]